Clinical Pharmacology (Phase I-IIa)
News, Events & Publications |
 |
News
February 20th, 2007
Medicine Is Put To The Test
A Honolulu Facility Pays People To Try Out New Drugs For Science
 Download PDF
January 31st, 2007
Covance Expands, Consolidates Research Clinic In Austin, TX
New facility increases Phase I capacity
November 9th, 2006
Covance Relocates Research Facility In Honolulu
Consolidated site provides access to key Asian population for bridge studies
September 22nd, 2006
Covance Expands Research Clinic In Daytona Beach
New facility expands Phase I capacity
May 31st, 2006
Covance Completes the Acquisition of the Phase I/IIA Business of Radiant Research Inc.
April 20th, 2006
Covance to Increase Phase I/IIa Capacity with Acquisition of Eight Early Clinical Development Sites from Radiant Research
August 23rd, 2005
Covance Increases Its Phase I Clinical Capacity With Acquisition of GFI Research Center
February 21st, 2005
Covance Clinical Research Unit in Leeds Opens New GMP Pharmacy
New investment meets the requirements of the European Clinical Trials Directive
Madison CRU Virtual
Tour on CD or DVD
Order Now
Leeds CRU Virtual
Tour on CD or DVD
Order Now
European Clinical Trials Directive: Impact on Phase I in the UK
Download PDF
Typical clinical development timeline: View Chart
Covance Central Diagnostics Certified as ISO 9001
Certification Positions Electrocardiogram and Imaging Services Provider as an Industry Leader |
|
Publications
Key Factors in the Safety Assessment of High-Risk Medicines
Peter Thomas, PhD and Karen Cornelissen, PhD
Covance Evolutions Newsletter
Volume 12, No. 3, February 2008
Download PDF
Designing a Comprehensive Cardiovascular Safety Testing Regimen
Ian McKenzie and Dusty Sarazan
Covance Evolutions Newsletter
Volume 10, No. 1, July 2005
Download PDF
cGMP Pharmacy at Leeds, UK Clinical Research Unit (CRU)
Covance's CRU in Leeds has commissioned a fully compliant cGMP pharmacy to meet the changing requirements described in the European Clinical Trials Directive.
Download PDF
Planning for the impact of the EU clinical trials directive on phase I studies
Karen Cornelissen
Covance Evolutions Newsletter
Volume 9, No. 3, September 2004
Download PDF
Service Profile: European Clinical Trials Directive: Impact on Phase I in the UK
Download PDF
Defining the Role of Drug-Drug Interaction Studies in the Development Pathway
Mary Westrick, PhD
Covance Evolutions Newsletter
Volume 6, No. 1, July 2001
Download PDF
A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Subcutaneous Dose, Safety, Tolerability And Pharmacokinetic Study In Healthy Male Subjects
S. D. Oliver, S. Bryson, J. Ward and S. V. Mitchell
Covance Clinical Research Unit, Leeds, United Kingdom
AMRAD Operations Pty Ltd, Victoria, Australia
The Use of Mixed Effects Models for the Analysis of Dose Proportionality in Phase I Clinical Trials
B. South and J. Sargeant
Covance Clinical Research Unit, Leeds, United Kingdom
The Use of Nonlinear Mixed Effects Models for the Analysis of Pharmacokinetic Data in Phase I Clinical Trials
T. Higgins
Covance Clinical Research Unit, Leeds, United Kingdom
Phase I, Single And Multiple Oral Dose, Safety, Tolerability And Pharmacokinetic Studies In Healthy Male Subjects
S. D. Oliver, C. Ward, J. Ward, H. Kato, Y. Saito and S. Furuta
Covance Clinical Research Unit, Leeds, United Kingdom
Zeria Pharmaceutical Co Ltd, Tokyo, Japan |
|
|
